There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease MACHINE LEARNING MODEL USING ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...